As previously reported, Scotiabank analyst Sung Ji Nam initiated coverage of Bio-Techne with an Outperform rating and $80 price target. The life science tools company has a decades-long track record of providing quality biological reagents for life sciences applications, but has also significantly expanded its addressable market over the last ten years with M&A, the analyst tells investors. The firm, which cites the company’s “industry-leading top-line growth and margin profiles,” believes Bio-Techne is one of the best positioned companies to outperform the life science tools market growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TECH:
- Macy’s upgraded, New York Community downgraded: Wall Street’s top analyst calls
- Bio-Techne price target lowered to $85 from $88 at Deutsche Bank
- Bio-Techne price target lowered to $80 from $86 at Craig-Hallum
- Bio-Techne price target raised to $73 from $68 at Baird
- Bio-Techne price target lowered to $87 from $92 at Stephens